Off-label uses by drug
| no. (%) | Indication | |
|---|---|---|
| Alemtuzumab | 1 (5.3) | Bone marrow aplasia |
| Azacitidine | 1 (5.3) | Acute myeloid leukaemia secondary to myelodysplastic syndrome in transplant candidate |
| Bendamustine | 1 (5.3) | Non-Hodgkin’s lymphoma in combination treatment |
| Bortezomib | 3 (15.8) | Multiple myeloma in combination with dexamethasone |
| Fotemustine | 1 (5.8) | Metastatic oligodendroglioma |
| Pemetrexed | 2 (10.5) | Second-line treatment in metastatic lung adenocarcinoma in combination with cisplatin |
| Rituximab | 8 (42.1) | Evans’syndrome Systemic lupus erythematosus Lupus glomerulopathy Waldeström’s macroglobulinaemia Wegener’s syndrome Idiopathic thrombocytopenic purpura Mantle cell lymphoma (two patients) |
| Trastuzumab | 2 (10,5) | Metastatic breast cancer in combination with vinorelbine |